Summit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC Wainwright
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $44.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 140.44% from the company’s current price. […]
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $44.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 140.44% from the company’s current price. […]
